浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Effects of andrographolide on angiogenesis in diabetic foot rats and its mechanism
- ZHONGGUO YAOFANG Vol. 34, Issue 17, Pages: 2128-2133(2023)
- 作者机构：
1.邢台市人民医院中医内科，河北 邢台 054000
2.邢台市人民医院放射科，河北 邢台 054000
3.邢台市人民医院内分泌科，河北 邢台 054000
4.邢台市人民医院耳鼻喉科，河北 邢台 054000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.17.14
CLC： R965;R285.5Published：15 September 2023，
Received：02 March 2023，
Revised：08 August 2023，
扫 描 看 全 文
张丽晓,戴守方,李蕾等.穿心莲内酯对糖尿病足大鼠血管生成的影响及机制 Δ[J].中国药房,2023,34(17):2128-2133.
ZHANG Lixiao,DAI Shoufang,LI Lei,et al.Effects of andrographolide on angiogenesis in diabetic foot rats and its mechanism[J].ZHONGGUO YAOFANG,2023,34(17):2128-2133.
张丽晓,戴守方,李蕾等.穿心莲内酯对糖尿病足大鼠血管生成的影响及机制 Δ[J].中国药房,2023,34(17):2128-2133. DOI： 10.6039/j.issn.1001-0408.2023.17.14.
ZHANG Lixiao,DAI Shoufang,LI Lei,et al.Effects of andrographolide on angiogenesis in diabetic foot rats and its mechanism[J].ZHONGGUO YAOFANG,2023,34(17):2128-2133. DOI： 10.6039/j.issn.1001-0408.2023.17.14.
摘要
目的
2
探究穿心莲内酯（Andro）对糖尿病足大鼠血管生成的影响，并基于Hippo-Yes相关蛋白（YAP）信号通路探索其作用机制。
方法
2
采用小剂量链脲佐菌素联合高脂高糖饮食复制2型糖尿病大鼠模型，在其建模成功的基础上，用烫伤法建立糖尿病足大鼠模型。将造模成功的大鼠随机分为5组，每组12只：Model组，Andro低、中、高剂量组（1、10、20 mg/kg）和抑制剂组（20 mg/kg Andro+100 mg/kg的Hippo-YAP信号通路特异性抑制剂维替泊芬）。另外取12只健康大鼠作为Control组。各组大鼠灌胃和腹腔注射溶剂或相应药物，每日1次，连续2周。给药结束后，检测大鼠创面愈合情况、空腹血糖（FBG）和空腹胰岛素（FINS）含量；以HE染色法观察大鼠创面组织损伤及毛细血管数；采用流式细胞仪进行大鼠外周血内皮祖细胞（EPCs）计数；采用全自动生化分析仪检测大鼠血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）含量；采用Western blot法检测各组大鼠创面组织中缺氧诱导因子1α（HIF-1α）、血管内皮生长因子（VEGF）及Hippo-YAP信号通路相关蛋白的表达情况。
结果
2
与Control组比较，Model组大鼠创面愈合率，毛细血管数，EPCs比例，HDL-C含量，HIF-1α、VEGF蛋白表达水平及哺乳动物Ste20样激酶1、大肿瘤抑制基因1、YAP蛋白的磷酸化水平均显著降低，FBG、FINS水平及TC、TG、LDL-C含量均显著升高（
P
＜0.05）。与Model组比较，Andro低、中、高剂量组大鼠上述指标均显著逆转，且呈剂量依赖性（
P
＜0.05）；维替泊芬减弱了Andro的上述逆转作用（
P
＜0.05）。
结论
2
Andro具有降低糖尿病足大鼠血糖、血脂，促进糖尿病足大鼠血管生成及创面愈合的作用，其作用机制可能与激活Hippo-YAP信号通路有关。
Abstract
OBJECTIVE
2
To investigate the effects of andrographolide （Andro） on angiogenesis in rats with diabetic foot and to explore its mechanism of action based on the Hippo-Yes-associated protein （YAP） signaling pathway.
METHODS
2
The rat model of type 2 diabetes was established by using low-dose streptozotocin combined with high-fat and high-glucose diet. On the basis of successful modeling， the rat model of diabetes foot was established by scalding. Model rats were randomly divided into 5 groups with 12 rats in each group： model group， Andro low-dose， medium-dose， and high-dose groups （1， 10， and 20 mg/kg）， as well as inhibitor group （20 mg/kg Andro+100 mg/kg of verteporfin， an specific inhibitor of Hippo-YAP signaling pathway）； other 12 healthy rats were included in the Control group. Rats in each group were intragastrically and intraperitoneally injected with solvents or corresponding drugs， once a day， for 2 consecutive weeks. The wound healing， fasting blood glucose （FBG） and fasting insulin （FINS） were detected in rats after medication. HE staining was performed to observe the tissue damage and capillary number of rat trauma； the number of endothelial progenitor cells （EPCs） in peripheral blood of rats was counted by using flow cytometry； the contents of serum total cholesterol （TC）， triglyceride （TG）， high-density lipoprotein cholesterol （HDL-C） and low-density lipoprotein cholesterol （LDL-C） in rats were determined by fully automatic biochemical analyzer； the expressions of hypoxia-inducible factor 1α （HIF-1α）， vascular endothelial growth factor （VEGF） and Hippo-YAP signaling pathway-related proteins in the traumatic tissues of rats in each group were detected by Western blot.
RESULTS
2
Compared with Control group， the wound healing rate， capillary number， the proportion of EPCs， HDL-C content， as well as the protein expression levels of HIF-1α and VEGF and the phosphorylation levels of mammalian Ste20-like kinase 1， large tumor suppressor gene 1 and YAP proteins were significantly reduced in the model group， while the FBG， FINS levels and TC， TG and LDL-C contents were significantly increased （
P
＜0.05）. Compared with model group， the above indexes were significantly reversed in Andro low-dose， medium-dose and high-dose group， in a dose-dependent manner （
P
＜0.05）； verteporfin attenuated the above reversal effect of Andro （
P
＜0.05）.
CONCLUSIONS
2
Andro has the effects of lowering blood glucose and blood lipids， promoting blood vessel formation and wound healing in rats with diabetic foot， and its mechanism of action may be related to the activation of Hippo-YAP signaling pathway.
关键词
穿心莲内酯糖尿病足血管生成Hippo-Yes相关蛋白信号通路
Keywords
diabetic footangiogenesisHippo-YAP signaling pathway
references
BANDYK D F. The diabetic foot：pathophysiology，evalua- tion，and treatment[J]. Semin Vasc Surg，2018，31（2/3/4）：43-48.
PITOCCO D，SPANU T，LEO M D，et al. Diabetic foot infections：a comprehensive overview[J]. Eur Rev Med Pharmacol Sci，2019，23（2 Suppl）：26-37.
REARDON R，SIMRING D，KIM B，et al. The diabetic foot ulcer[J]. Aust J Gen Pract，2020，49（5）：250-255.
ZHU L Y，QIAN J Q，JIANG Y N，et al. PlGF reduction compromises angiogenesis in diabetic foot disease through macrophages[J]. Front Immunol，2021，12：736153.
BURGOS R A，ALARCÓN P，QUIROGA J，et al. Andrographolide，an anti-inflammatory multitarget drug：all roads lead to cellular metabolism[J]. Molecules，2020，26（1）：5.
JI X Q，LI C Z，OU Y T，et al. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway[J]. Mol Cell Endocrinol，2016，437：268-279.
LIANG E，LIU X，DU Z，et al. Andrographolide ameliorates diabetic cardiomyopathy in mice by blockage of oxidative damage and NF-κB-mediated inflammation[J]. Oxid Med Cell Longev，2018，2018：9086747.
PARK J A，KWON Y G. Hippo-YAP/TAZ signaling in angiogenesis[J]. BMB Rep，2018，51（3）：157-162.
HE J L，BAO Q K，YAN M，et al. The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease[J]. Br J Pharmacol，2018，175（8）：1354-1361.
ZHU X L，SHAN Y，YU M S，et al. Tetramethylpyrazine ameliorates peritoneal angiogenesis by regulating VEGF/Hippo/YAP signaling[J]. Front Pharmacol，2021，12：649581.
唐辉，姚志浩，罗道文，等. 高脂高糖饮食结合链脲佐菌素建立2型糖尿病性骨质疏松症大鼠模型[J]. 中国组织工程研究，2021，25（8）：1207-1211.
胡锦庆，巴元明，李鸣，等. 天楼解毒消肿散治疗大鼠糖尿病足的作用机制研究[J]. 中华中医药杂志，2019，34（12）：5868-5872.
WEI H L，WANG F H，WANG Y，et al. Verteporfin suppresses cell survival，angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex[J]. Cancer Sci，2017，108（3）：478-487.
邵恳，杨昌明，周芹，等. 人参皂苷Rh2对高脂饮食大鼠心肌缺血再灌注损伤的保护作用及其机制[J]. 中国临床药理学杂志，2018，34（17）：2094-2096.
LIM J Z M，NG N S L，THOMAS C. Prevention and treatment of diabetic foot ulcers[J]. J R Soc Med，2017，110（3）：104-109.
辛燕，李伟，刘大龙. 二甲双胍对糖尿病足溃疡愈合的影响[J]. 糖尿病新世界，2020，23（2）：193-195.
ALIPANAH-MOGHADAM R，MEHRI A，MANAFI F，et al. Andrographolide，a novel inducer of apelin gene expression[J]. J Ethnopharmacol，2021，280：114487.
WONG T S，ISMAIL H F，HASHIM Z，et al. Synergistic antihyperglycaemic effect of combination therapy with gallic acid and andrographolide in streptozotocin-induced diabetic rats[J]. Biocatal Agric Biotechnol，2019，18：101048.
LIN C J，LAN Y M，OU M Q，et al. Expression of miR-217 and HIF-1α/VEGF pathway in patients with diabetic foot ulcer and its effect on angiogenesis of diabetic foot ulcer rats[J]. J Endocrinol Invest，2019，42（11）：1307-1317.
KAUSHIK K，DAS A. Endothelial progenitor cell therapy for chronic wound tissue regeneration[J]. Cytotherapy，2019，21（11）：1137-1150.
BAI S W，YIN Q Q，DONG T，et al. Endothelial progenitor cell-derived exosomes ameliorate endothelial dysfunction in a mouse model of diabetes[J]. Biomedecine Pharmacother，2020，131：110756.
YANG S F，WANG S S，CHEN L，et al. Neutrophil extracellular traps delay diabetic wound healing by inducing endothelial-to-mesenchymal transition via the Hippo pathway[J]. Int J Biol Sci，2023，19（1）：347-361.
0
Views
1
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.